Mesoblast Limited (MSB) Q2 2026 Earnings Report

The call communicated strong commercial momentum from the Ryoncil launch (USD 49M H1 revenue), industry-leading gross margins (93%), broad payer coverage, rapid center onboarding and multiple near-term regulatory and clinical milestones (Revascor BLA next quarter; back pain enrollment completion and 2027 BLA). The company also strengthened its balance sheet with USD 130M cash and a USD 125M credit facility. Offsetting risks include a sharp increase in R&D and SG&A spending, reliance on Ryoncil for most revenues, ongoing manufacturing/CMC items ahead of filings, and near-term cash usage (USD 30.3M H1) with a tranche deadline in June 2026. Overall, the positive operational, clinical and financial developments materially outweigh the execution and expense risks.

Management reiterated FY2026 guidance and laid out key metrics: H1 revenues were $51.3M with Ryoncil net product revenues of $49M and a 93% gross margin (gross margin excl. amortization ~$44.2M); direct selling costs $7.7M, R&D $46.2M, SG&A $28.5M, net loss $40.2M, and H1 operating cash use $30.3M. Cash was $130M at Dec 31 and Mesoblast has a $125M credit facility (first tranche $75M drawn, $50M available through June 2026); the subordinated royalty facility is expected to be fully repaid by mid‑2026 and operating cash use is expected to decline in H2. For Ryoncil they expect full‑year net revenues of $110–120M, target ~20% pediatric penetration by year‑end (based on a ~375‑patient base and a 40% peak‑share assumption), have onboarded 49 centers (30 with formulary listings; 13 using Optum Frontier), secured coverage for >280M lives with Medicaid in all states and J‑code J3402 effective Oct 1, and plan label expansion into adults (market ~3x pediatric). Pipeline milestones include rexlemestrocel‑L (404‑patient Phase III completed; confirmatory 300‑patient trial enrolling with enrollment expected by Mar/Apr and a 2027 data/BLA timeline) and Revascor (LVAD II: 159‑patient 2:1 RCT plus supportive 30‑patient study showing ~5‑fold reduction in major bleeding through 12 months and survival benefit) with a BLA filing for full approval planned next quarter.